Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:


Last Updated: December 7, 2022

CARBAMAZEPINE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

When do Carbamazepine patents expire, and when can generic versions of Carbamazepine launch?

Carbamazepine is a drug marketed by Apotex Inc, Nostrum Labs Inc, Taro, Teva Pharms, Novitium Pharma, Wockhardt Bio Ag, Jubilant Cadista, Taro Pharm Inds, Torrent Pharms, Anbison Lab, Cspc Ouyi, Umedica Labs Pvt Ltd, Unique Pharm, Zhejiang Jiuzhou, Zydus Pharms, Actavis Elizabeth, Inwood Labs, Pliva, Unichem, Usl Pharma, Vgyaan, and Warner Chilcott. and is included in twenty-eight NDAs.

The generic ingredient in CARBAMAZEPINE is carbamazepine. There are twenty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the carbamazepine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Carbamazepine

A generic version of CARBAMAZEPINE was approved as carbamazepine by TARO on October 3rd, 1996.

  Try it Free

Drug patent expirations by year for CARBAMAZEPINE

See drug prices for CARBAMAZEPINE

Drug Sales Revenue Trends for CARBAMAZEPINE

See drug sales revenues for CARBAMAZEPINE

Recent Clinical Trials for CARBAMAZEPINE

Identify potential brand extensions & 505(b)(2) entrants

Cerevel Therapeutics, LLCPhase 1
Enanta Pharmaceuticals, IncPhase 1
Janssen Pharmaceutica N.V., BelgiumPhase 1

See all CARBAMAZEPINE clinical trials

Medical Subject Heading (MeSH) Categories for CARBAMAZEPINE
Anatomical Therapeutic Chemical (ATC) Classes for CARBAMAZEPINE
Paragraph IV (Patent) Challenges for CARBAMAZEPINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EQUETRO Extended-release Capsules carbamazepine 100 mg 021710 1 2014-05-23
EQUETRO Extended-release Capsules carbamazepine 200 mg and 300 mg 021710 1 2007-08-21
CARBATROL Extended-release Capsules carbamazepine 100 mg and 200 mg 020712 1 2006-02-02
TEGRETOL-XR Extended-release Tablets carbamazepine 100 mg 020234 1 2005-12-30

US Patents and Regulatory Information for CARBAMAZEPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Elizabeth CARBAMAZEPINE carbamazepine TABLET;ORAL 071696-001 Nov 9, 1987 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Unique Pharm CARBAMAZEPINE carbamazepine TABLET, EXTENDED RELEASE;ORAL 211623-001 Apr 24, 2020 AB RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Torrent Pharms CARBAMAZEPINE carbamazepine TABLET;ORAL 077272-004 Dec 7, 2005 RX No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.